# Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis

> **NCT04925557** · PHASE2,PHASE3 · TERMINATED · sponsor: **State University of New York at Buffalo** · enrollment: 8 (actual)

## Conditions studied

- Secondary-progressive Multiple Sclerosis

## Interventions

- **DRUG:** Mayzent
- **DRUG:** Ocrevus

## Key facts

- **NCT ID:** NCT04925557
- **Lead sponsor:** State University of New York at Buffalo
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-11-13
- **Primary completion:** 2023-06-01
- **Final completion:** 2023-08-05
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Lack of recruitment
- **Last updated:** 2025-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04925557

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04925557, "Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04925557. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*